Pacira earnings missed by $0.03, revenue fell short of estimates

Pacira (PCRX) reported Q3 EPS of $0.70, missing estimates by $0.03, with revenue at $176.65M, below the $182.86M consensus. The stock is up 49.43% over 3 months and 65.22% over 12 months. InvestingPro rates its financial health as 'good performance'.

Original reporting
Published Nov 8, 2026, 4:17 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 8, 2026, 4:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PCRX
Bearish
high confidence
Mentioned
$PCRX
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PCRXBearishMed
01

Why it matters

The miss may lead to a short‑term sell‑off, but longer‑term fundamentals could remain intact.

02

Market read

Earnings miss for a small‑cap biotech; relevant for traders focused on earnings volatility.

03

What to watch

Potential upside from upcoming product launches or cost‑reduction initiatives not reflected in the earnings release.

Relevance 6/10Novelty 6/10Timing: post-market reaction

Background

Pacira Therapeutics (NASDAQ: PCRX) reported its third‑quarter results, missing both earnings and revenue estimates.

Company-level read

Ticker impact

$PCRXBearishHigh confidence
Context

Q3 earnings miss: EPS $0.70 vs $0.73 estimate and revenue $176.65M vs $182.86M estimate.

Expected impact

likely downside as investors price in weaker results

Evidence & confidence

Both EPS and revenue fell short of consensus, a clear negative catalyst for the stock.

Market effects

May weigh on the broader pain management/medical device sector if peers face similar pressure.

Limited to US small‑cap biotech/healthcare segment.

Low global impact; primarily a company‑specific event.

Counterpoint

If the miss is viewed as a temporary setback and the company has strong pipeline, the dip could be a buying opportunity.

Key entities

  • Pacira Therapeutics

    US‑listed biotech firm reporting Q3 results.

Related articles

$VTRSMedAI 8/10

Viatris Completes Acquisition of Pacira BioSciences

Viatris Inc. (VTRS) completed its acquisition of Pacira BioSciences (PCRX) for $36.50 per share. The deal, announced in October, aims to strengthen Viatris's U.S. pain management business. Pacira's shares will be delisted from Nasdaq, and Viatris expects the acquisition to add $90M-$100M in revenue for the rest of 2026.

$PCRXLow

Pacira BioSciences, Inc. (PCRX): RDF has the right to terminate the agreement for an uncured material breach by the Company, in connection with its bankruptcy or insolvency or if it directly…

Pacira BioSciences, Inc. (PCRX) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure. As previously disclosed, pursuant to an agreement entered into between the Research Development Foundation (“RDF”) and a wholly-owned subsidiary of Pacira BioSciences, Inc. (the “Company” or “Pacira”), the Company was required to pay RDF a low